New hope for teens with severe hay fever: xolair shows promise
NCT ID NCT04648930
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested Xolair (omalizumab) in 50 teenagers aged 12 to 17 with severe seasonal allergic rhinitis (hay fever) that standard treatments couldn't control. Researchers tracked side effects and how much symptoms improved. The goal was to see if Xolair is safe and effective in this age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Xolair (omalizumab)
- What this could lead to
- If successful, this could show that Xolair is a safe and effective option for teenagers with severe seasonal allergies that don't respond to usual treatments.
- What could go wrong
- This was a small, uncontrolled study with only 50 participants, so results may not apply to everyone. Side effects like injection reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ancient herbal blend put to the test against hay fever
- Can a pinpoint pollen dose unmask allergy triggers?
- Can an antihistamine–steroid combo pill beat standard allergy meds?
- Allergy tablets under the tongue may cut hay fever drug use for years, massive real-world study suggests
- Allergy study seeks to pinpoint those most bothered by cats and birch pollen
- Dog allergy vaccine shows promise in small swedish trial